GlassScriptPhysician profile
Lindsay Lee Gray
NPI 1508407594
$3,867.66
in general payments reported to CMS, 2019-2025
38 companies · $984 in 2025
The $984 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $913 · 2022: $654 · 2023: $558 · 2024: $759 · 2025: $984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,300.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,045.55 | 2021-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $429.17 | 2022-2025 | |
| Amgen INC. | $230.78 | 2022-2025 | Krystexxa, Tavneos |
| Travere Therapeutics, INC. | $196.36 | 2022-2025 | Filspari |
| Horizon Therapeutics Plc | $142.98 | 2021-2023 | Krystexxa |
| Teva Pharmaceuticals USA, INC. | $137.75 | 2024 | Austedo Xr |
| Vifor Pharma, INC. | $136.98 | 2021 | |
| Alexion Pharmaceuticals, INC. | $135.00 | 2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $125.95 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $122.77 | 2021-2025 | Jynarque, Voyxact |
| Abbvie INC. | $121.37 | 2022 | |
| Apellis Pharmaceuticals, INC. | $119.20 | 2025 | Empaveli |
| Daiichi Sankyo INC. | $116.61 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.51 | 2024 | Jardiance |
| Calliditas Therapeutics US INC. | $102.78 | 2024-2025 | Tarpeyo |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $48.49 | 2023 | Lupkynis |
| Regeneron Healthcare Solutions, INC. | $48.33 | 2025 | Dupixent |
| Genzyme Corporation | $47.77 | 2024-2025 | |
| Mylan Specialty L.P. | $37.16 | 2024 | Yupelri |
| Outset Medical INC | $35.79 | 2025 | |
| Kyowa Kirin, INC. | $35.32 | 2023 | Crysvita |
| Abiomed | $34.92 | 2025 | |
| Novo Nordisk INC | $33.51 | 2024-2025 | Ozempic, Wegovy |
| Avadel Cns Pharmaceuticals, LLC | $27.69 | 2025 | Lumryz |
| Resmed Corp | $27.47 | 2025 | |
| Tactile Systems Technology INC | $21.67 | 2021 | |
| Kci USA, INC. | $20.11 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.91 | 2023 | Oxlumo |
| Akebia Therapeutics INC | $18.87 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.79 | 2023 | Gattex |
| Glaxosmithkline, LLC. | $17.38 | 2021 | |
| Verona Pharma, INC. | $16.96 | 2025 | Ohtuvayre |
| Ardelyx, INC. | $15.56 | 2024 | Ibsrela |
| Ultragenyx Pharmaceutical INC. | $15.51 | 2023 | |
| Recordati_rare_diseases_inc. | $15.49 | 2023 | Signifor Lar, Isturisa |
| Corcept Therapeutics | $14.57 | 2024 | Korlym |
| Baxter Healthcare | $14.23 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Fresenius USA Marketing, INC. | $13.40 | 2023 | Velphoro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.